Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Registration Number
- NCT00465621
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Open-angle glaucoma
- ocular hypertension
Exclusion Criteria
- VA worse than 0.60
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Mean IP Change from Baseline
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AL-37807's IOP-lowering effects compared to Xalatan in open-angle glaucoma?
How does AL-37807 0.05%, 0.1%, and 0.2% compare to Xalatan in Phase 2 trials for ocular hypertension?
Which biomarkers correlate with response to AL-37807 in patients with primary open-angle glaucoma or ocular hypertension?
What are the safety profiles and adverse event management strategies for AL-37807 versus Xalatan in Phase 2 studies?
How does Alcon Research's AL-37807 compare to other prostaglandin analogs like bimatoprost in treating ocular hypertension?
Trial Locations
- Locations (1)
Atlanta
🇺🇸Atlanta, Georgia, United States
Atlanta🇺🇸Atlanta, Georgia, United States